FDA Accepts ANDA for Tofacitinib Citrate by YAOPHARMA
The FDA has accepted the Abbreviated New Drug Application (ANDA) for Tofacitinib Citrate submitted by YAOPHARMA.
Asset / Drug
Drug and asset intelligence for YAOPHARMA with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
JAK Inhibitor
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.